Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Neurobiol Dis. 2010 Oct 23;41(2):436–444. doi: 10.1016/j.nbd.2010.10.015

Figure 1.

Figure 1

Cortical BDNF protein levels are elevated in R6/2 mice that received ampakine treatments. (A) Representative western blot from Cohort 2 mice (treated for 7 weeks beginning at 3 weeks of age), shows that mature (m) BDNF (~14–15 kDa) protein levels are lower in parietal cortex of vehicle (veh)-treated R6/2 mice compared WTs at 10 weeks of age and that the difference was attenuated in R6/2s given CX929 (929) (mice were killed 18 hours after the last injection). Corresponding actin immunobands from the stripped and re-probed blot is shown at bottom (n=8 for WT-CX929, n=10 for WT-Veh, n=8 for R6/2-Veh, n=9 for R6/2-CX929). (B) Representative western blot of striatal samples from a subset of Cohort 2 mice treated with vehicle or ampakine (n=3/group). (C) Densitometric analysis of western blots showed that for neocortex (black bars) mBDNF protein levels were lower in vehicle-treated R6/2 mice relative to WTs (**p = 0.002) and that CX929 treatment elevated BDNF protein levels in the R6/2s (**p = 0.01) to WT levels (p>0.05): Group mean striatal BDNF levels (grey bars) were 40% higher in R6/2 mice given CX929 versus those given vehicle (*p = 0.019). All p-values are from one-tail Student’s t-tests.